Skip to content
OpenCapital
Get started

Ligand Pharmaceuticals LGND Increase (decrease) in contract liabilities and current deferred income

Increase (decrease) in contract liabilities and current deferred income at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-$20.82M-51.8%
Zymeworks logo
ZymeworksZYME
-$340K+83.8%
ALN
Alnylam PharmaceuticalsALNY
——

Other financials

Income statement

See full
Revenue$51.7M+14.1%
Operating income$17.4M+148%
Net income-$13.3M+68.6%
EPS (diluted)-$0.67+69.7%

Balance sheet

See full
Cash & equivalents$115.1M+140%
Total debt$5.1M+14.2%
Total equity$997.3M+25.4%
Total assets$1.5B+69.2%

Cash flow

See full
Operating cash flow$48.7M+291%
CapEx$228.0K+6.5%
Free cash flow$48.5M+289%

Valuation

See full
Market cap$5.71B+96.7%
Enterprise value$5.6B+95.4%
P/E37.2×—
P/S20.8×+4.8×

Profitability

See full
Gross margin91.9%—
Operating margin34.5%+23.0pp
Net margin55.9%+35.7pp
FCF margin44.8%+16.8pp

Returns & leverage

See full
Return on equity17.1%+11.5pp
Debt / equity0×0.0×
Current ratio21.3×+16.0×

Where this comes from

Reported directly by Ligand Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.

The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ligand Pharmaceuticals's increase (decrease) in contract liabilities and current deferred income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ligand Pharmaceuticals's increase (decrease) in contract liabilities and current deferred income?
Ligand Pharmaceuticals (LGND) reported increase (decrease) in contract liabilities and current deferred income of $0 in Q1 2026.
How has Ligand Pharmaceuticals's increase (decrease) in contract liabilities and current deferred income changed year-over-year?
Ligand Pharmaceuticals's increase (decrease) in contract liabilities and current deferred income increased by 100.0% year-over-year, from -$293K to $0.
What is the long-term trend for Ligand Pharmaceuticals's increase (decrease) in contract liabilities and current deferred income?
Over 2 years (2021 to 2024), Ligand Pharmaceuticals's increase (decrease) in contract liabilities and current deferred income has grown at a -72.9% compound annual growth rate (CAGR), from -$17.87M to -$1.31M.